Results 191 to 200 of about 30,338 (335)

An experimental investigation of unique high stepup boost converter for electric vehicle and solar photovoltaic. [PDF]

Sci Rep
Mariprasath T, Shivashimpiger S, Rivera M, Wheeler P, Reddy MPP, Ali SM, Peruthambi V, Bonaldo J.   +7 more
europepmc   +1 more source

SKALE: An Interpretable Multiscale Machine Learning Model for Decoding Phase‐Specific Protein Aggregation in Neurodegenerative Proteinopathies

Aggregate, Volume 7, Issue 2, February 2026.
Protein aggregation drives diverse degenerative diseases, yet its molecular origins are difficult to predict. SKALE uses interpretable machine learning to link sequence, structure, and dynamics, revealing how local structural weakening triggers aggregation.
Wei Xuan Wilson Loo, Jia Shen Sio, Keyin Yap, Yan Shan Loo, Hui Xuan Lim, Shuangyue Zhang, Huitao Liu, Chen Seng Ng   +7 more
wiley   +1 more source

GaN HEMTs-based compact power factor corrected 96.1% peak efficiency LED driver with gate assisted circuit. [PDF]

Sci Rep
Faizan M, Qian Z, Zhu H, Fan S, Yousaf MZ, Bajaj M, Zhichu C, Aziz A.   +7 more
europepmc   +1 more source

Terahertz-to-infrared converters for imaging the human skin cancer: challenges and feasibility. [PDF]

J Med Imaging (Bellingham), 2023
Moldosanov K, Bykov A, Kairyev N, Khodzitsky M, Kropotov G, Lelevkin V, Meglinski I, Postnikov A, Shakhmin A.   +8 more
europepmc   +1 more source

Distinct alterations of adiponectin, fibroblast growth factor 21 (FGF‐21), and insulin‐like growth factor binding protein 2 (IGFBP‐2) link dysmetabolism with cognitive decline across the Alzheimer's disease spectrum

Alzheimer's &Dementia, Volume 22, Issue 2, February 2026.
Abstract INTRODUCTION Metabolic disorders are risk factors for Alzheimer's disease (AD), although underlying mechanisms remain unclear. We investigated the relationship between peripheral metabolic markers – adiponectin, fibroblast growth factor 21 (FGF‐21), and insulin‐like growth factor binding protein 2 (IGFBP‐2) – and AD.
Caroline Dallaire‐Théroux, Helena L. Denis, Rosalie Cottez, Cyntia Tremblay, Amélie Provencher, Josue Valentin‐Escalera, Manon Leclerc, Andreanne Loiselle, Marine Tournissac, Olivier Potvin, Sylvie Belleville, Anne Gangloff, Frederic Picard, Henrik Zetterberg, Consortium for the Early Identification of Alzheimer's Disease – Quebec (CIMA‐Q), Frédéric Calon   +15 more
wiley   +1 more source

Hybrid fuzzy-MPC based multi-objective control strategy for fast charging of electric vehicles with advanced battery thermal management and renewable grid support. [PDF]

Sci Rep
Yadav IC, Bajpai RS, Gupta S, Shukla A.
europepmc   +1 more source

Proteomics reveals three molecular subtypes of Alzheimer's disease with distinct progression patterns

Alzheimer's &Dementia, Volume 22, Issue 2, February 2026.
Abstract INTRODUCTION Alzheimer's disease (AD) shows marked molecular heterogeneity. Defining biological subtypes may refine diagnosis and treatment. METHODS We analyzed cerebrospinal fluid (CSF) proteomics and longitudinal data from 550 participants in the Alzheimer's Disease Neuroimaging Initiative with up to 16.5 years of follow‐up. We profiled 6361
Xiao‐He Hou, Wei Zhang, Kairan Kang, Yifei Jin, Peng Ren, Linbo Wang, Zeyu Li, Yuzhu Li, Jia You, Bei Zhang, Qing Ma, for the Alzheimer's Disease Neuroimaging Initiative, Fang Xie, Jin‐Tai Yu, Jian‐Feng Feng, Wei Cheng   +15 more
wiley   +1 more source

A total loss minimization modulation for series-resonant dual-active-bridge dc-dc converter with triple phase shift control. [PDF]

Sci Rep
Zhou S, Wang J, Tang J.
europepmc   +1 more source

A Composite DC-DC Converter Based on the Versatile Buck-Boost Topology for Electric Vehicle Applications. [PDF]

Sensors (Basel), 2022
González-Castaño C, Restrepo C, Flores-Bahamonde F, Rodriguez J.   +3 more
europepmc   +1 more source

Revising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assays

Alzheimer's &Dementia, Volume 22, Issue 2, February 2026.
Abstract INTRODUCTION Automated cerebrospinal fluid (CSF) biomarker assays have largely replaced manual immunoassays for measuring amyloid pathology in CSF. We refitted and validated the ABIDE model, predicting progression from mild cognitive impairment (MCI) to dementia, with CSF measurements from the automated Elecsys platform.
Pieter J. van der Veere, Argonde C. van Harten, Ingrid S. van Maurik, Charlotte E. Teunissen, Frederik Barkhof, Stephanie J. B. Vos, Lutz Froelich, Johannes Kornhuber, Jens Wiltfang, Wolfgang Maier, Oliver Peters, Eckart Rüther, Giovanni B. Frisoni, Luiza Spiru, Yvonne Freund‐Levi, Åsa K. Wallin, Harald Hampel, Magda Tsolaki, Iwona Kłoszewska, Patrizia Mecocci, Bruno Vellas, Simon Lovestone, Samantha Galluzzi, Sanna‐Kaisa Herukka, Isabel Santana, I. Baldeiras, Alexandre de Mendonca, Dina Silva, Gael Chetelat, Géraldine Poisnel, Pieter Jelle Visser, Sterling C. Johnson, Erik Stormrud, Oskar Hansson, Sebastian Palmqvist, Gerard Piñol‐Ripoll, for the Alzheimer's Disease Neuroimaging Initiative, Johannes Berkhof, Wiesje M. van der Flier   +38 more
wiley   +1 more source